Project 1: Establishing a robust functional cure
项目 1:建立强大的功能性治疗方法
基本信息
- 批准号:10381477
- 负责人:
- 金额:$ 50.87万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-04-15 至 2023-02-28
- 项目状态:已结题
- 来源:
- 关键词:AddressAnimalsAntibodiesAntibody ResponseCD4 AntigensCapsidCellsCollaborationsDataDependovirusDisease remissionDoseEpitopesEvaluationExcisionFc domainGlycoproteinsGoalsHIV Envelope Protein gp120HIV-1HIV-2HumanImmuneIn VitroInfectionMacacaMacaca mulattaMeasuresMediatingMonkeysMusPatientsPatternPropertyProphylactic treatmentProvirusesReportingResistanceResourcesSIVSafetySerumTestingTherapeuticTimeVaccinationVariantViralViral reservoirVirusVirus Replicationantibody-dependent cell cytotoxicityantiretroviral therapybasecostdesignfitnessimmune clearanceimmunogenicimmunogenicityimprovedmimeticsneutralizing antibodypeptidomimeticspromotersimian human immunodeficiency virustyrosine O-sulfatevectorvector genome
项目摘要
PROJECT SUMMARY (Project 1 – Robust functional cures with AAV-expressed eCD4-Ig)
eCD4-Ig is a potent and exceptionally broad fusion of the first two domains of CD4 to an antibody Fc
domain and a short tyrosine-sulfated coreceptor-mimetic peptide. In rhesus macaques, adeno-associated
virus (AAV)-expressed eCD4-Ig mediates consistent and very effective protection against SHIV-AD8 and
SIVmac239. eCD4-Ig also has properties that make it especially useful for establishing a functional cure in
rhesus macaques and perhaps in humans. These include its potency, breadth, difficulty-of-escape, low
immunogenicity when expressed by AAV, consistent expression by AAV, potent intrinsic ADCC activity, and
collaboration with serum antibodies to mediate ADCC. These properties allow eCD4-Ig to circumvent two
major problems associated with using AAV-expressed antibodies to establish functional cures, namely
immune clearance and viral escape. In preliminary data we show that AAV-expressed eCD4-Ig can
suppress replication of SHIV-AD8 for more than a year in 5 of 6 macaques. However we also show that,
when compared to the “Monkey monkey” described in Project 2, this suppression was less robust, meaning
that consistent ‘blipping’ of virus was observed in most eCD4-Ig-suppressed animals. Because the Miami
monkey expresses roughly 10 times the amount of total antibody observed in these eCD4-Ig-expressing
macaques, we hypothesize that greater expression of eCD4-Ig will result in more robust functional cures.
The goals of this project are thus to increase AAV-mediated expression of eCD4-Ig, to establish robust
functional cures in SHIV-AD8 and SIVmac239-infected macaques, to amplify the ADCC activities in these
macaques by stimulating host antibody responses to epitopes unmasked by eCD4-Ig, to establish a
consistent platform that will allow for evaluation of latency reversing agents, and to ask whether long-term
expression of eCD4-Ig by itself can impact the viral reservoir. These studies will improve and help
understand a viable approach to establishing similar functional cures in humans.
项目总结(项目1 -AAV表达的eCD 4-IG的稳健功能性治愈)
eCD 4-IG是CD 4的前两个结构域与抗体Fc的有效且异常广泛的融合物
结构域和短的酪氨酸硫酸化辅助受体模拟肽。在恒河猴中,腺相关性
病毒(AAV)表达的eCD 4-IG介导针对SHIV-AD 8的一致且非常有效的保护,
SIVmac239. eCD 4-IG还具有使其特别可用于建立功能性治愈的性质,
恒河猴和人类。这些包括其效力,广度,逃脱难度,低
当由AAV表达时的免疫原性、由AAV的一致表达、有效的内在ADCC活性,以及
与血清抗体协同介导ADCC。这些特性允许eCD 4-IG绕过两个
与使用AAV表达的抗体建立功能性治愈相关的主要问题,即
免疫清除和病毒逃逸。在初步的数据中,我们表明AAV表达的eCD 4-IG可以在细胞内表达。
在6只猕猴中5只中抑制SHIV-AD 8复制超过一年。然而,我们也表明,
当与项目2中描述的“猴子”相比时,这种抑制不太稳健,这意味着
在大多数eCD 4-Ig抑制的动物中观察到一致的病毒“起泡”。因为迈阿密
在这些表达eCD 4-Ig的猴子中观察到的总抗体量的大约10倍,
在猕猴中,我们假设eCD 4-IG的更高表达将导致更稳健的功能性治愈。
因此,本项目的目标是增加eCD 4-IG的AAV介导的表达,以建立稳健的免疫原性。
在SHIV-AD 8和SIVmac 239感染的猕猴中进行功能性治疗,以放大这些猕猴中的ADCC活性。
通过刺激宿主抗体对eCD 4-IG暴露的表位的应答,
一致的平台,将允许评估延迟逆转剂,并询问是否长期
eCD 4-IG自身的表达可影响病毒库。这些研究将改善和帮助
了解在人类中建立类似功能性治疗的可行方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mauricio de Aguiar Martins其他文献
Mauricio de Aguiar Martins的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mauricio de Aguiar Martins', 18)}}的其他基金
Overcoming pre-existing immunity to AAV to enhance AAV-based HIV immunotherapies
克服预先存在的 AAV 免疫力,增强基于 AAV 的 HIV 免疫疗法
- 批准号:
10626436 - 财政年份:2022
- 资助金额:
$ 50.87万 - 项目类别:
AAV-mediated delivery of eCD4-Ig for prevention and treatment of perinatal HIV infection
AAV 介导的 eCD4-Ig 递送用于预防和治疗围产期 HIV 感染
- 批准号:
10082720 - 财政年份:2020
- 资助金额:
$ 50.87万 - 项目类别:
eCD4-Ig for preventing and treating obstetric HIV infection
eCD4-Ig 用于预防和治疗产科 HIV 感染
- 批准号:
10644034 - 财政年份:2020
- 资助金额:
$ 50.87万 - 项目类别:
AAV-mediated delivery of eCD4-Ig for prevention and treatment of perinatal HIV infection
AAV 介导的 eCD4-Ig 递送用于预防和治疗围产期 HIV 感染
- 批准号:
10406312 - 财政年份:2020
- 资助金额:
$ 50.87万 - 项目类别:
AAV-mediated delivery of eCD4-Ig for prevention and treatment of perinatal HIV infection
AAV 介导的 eCD4-Ig 递送用于预防和治疗围产期 HIV 感染
- 批准号:
10644033 - 财政年份:2020
- 资助金额:
$ 50.87万 - 项目类别:
eCD4-Ig for preventing and treating obstetric HIV infection
eCD4-Ig 用于预防和治疗产科 HIV 感染
- 批准号:
10238165 - 财政年份:2020
- 资助金额:
$ 50.87万 - 项目类别:
eCD4-Ig for preventing and treating obstetric HIV infection
eCD4-Ig 用于预防和治疗产科 HIV 感染
- 批准号:
10082182 - 财政年份:2020
- 资助金额:
$ 50.87万 - 项目类别:
A nonhuman primate model to study the immunological effects of feminizing hormone therapy in transgender women
用于研究跨性别女性女性化激素治疗的免疫学影响的非人类灵长类动物模型
- 批准号:
10307630 - 财政年份:2020
- 资助金额:
$ 50.87万 - 项目类别:
A nonhuman primate model to study the immunological effects of feminizing hormone therapy in transgender women
用于研究跨性别女性女性化激素治疗的免疫学影响的非人类灵长类动物模型
- 批准号:
10162920 - 财政年份:2020
- 资助金额:
$ 50.87万 - 项目类别:
eCD4-Ig for preventing and treating obstetric HIV infection
eCD4-Ig 用于预防和治疗产科 HIV 感染
- 批准号:
10415989 - 财政年份:2020
- 资助金额:
$ 50.87万 - 项目类别:
相似海外基金
The earliest exploration of land by animals: from trace fossils to numerical analyses
动物对陆地的最早探索:从痕迹化石到数值分析
- 批准号:
EP/Z000920/1 - 财政年份:2025
- 资助金额:
$ 50.87万 - 项目类别:
Fellowship
Animals and geopolitics in South Asian borderlands
南亚边境地区的动物和地缘政治
- 批准号:
FT230100276 - 财政年份:2024
- 资助金额:
$ 50.87万 - 项目类别:
ARC Future Fellowships
The function of the RNA methylome in animals
RNA甲基化组在动物中的功能
- 批准号:
MR/X024261/1 - 财政年份:2024
- 资助金额:
$ 50.87万 - 项目类别:
Fellowship
Ecological and phylogenomic insights into infectious diseases in animals
对动物传染病的生态学和系统发育学见解
- 批准号:
DE240100388 - 财政年份:2024
- 资助金额:
$ 50.87万 - 项目类别:
Discovery Early Career Researcher Award
Zootropolis: Multi-species archaeological, ecological and historical approaches to animals in Medieval urban Scotland
Zootropolis:苏格兰中世纪城市动物的多物种考古、生态和历史方法
- 批准号:
2889694 - 财政年份:2023
- 资助金额:
$ 50.87万 - 项目类别:
Studentship
Using novel modelling approaches to investigate the evolution of symmetry in early animals.
使用新颖的建模方法来研究早期动物的对称性进化。
- 批准号:
2842926 - 财政年份:2023
- 资助金额:
$ 50.87万 - 项目类别:
Studentship
Study of human late fetal lung tissue and 3D in vitro organoids to replace and reduce animals in lung developmental research
研究人类晚期胎儿肺组织和 3D 体外类器官在肺发育研究中替代和减少动物
- 批准号:
NC/X001644/1 - 财政年份:2023
- 资助金额:
$ 50.87万 - 项目类别:
Training Grant
RUI: Unilateral Lasing in Underwater Animals
RUI:水下动物的单侧激光攻击
- 批准号:
2337595 - 财政年份:2023
- 资助金额:
$ 50.87万 - 项目类别:
Continuing Grant
RUI:OSIB:The effects of high disease risk on uninfected animals
RUI:OSIB:高疾病风险对未感染动物的影响
- 批准号:
2232190 - 财政年份:2023
- 资助金额:
$ 50.87万 - 项目类别:
Continuing Grant
A method for identifying taxonomy of plants and animals in metagenomic samples
一种识别宏基因组样本中植物和动物分类的方法
- 批准号:
23K17514 - 财政年份:2023
- 资助金额:
$ 50.87万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)